The results from this study, if positive, will be used by Clavis Pharma to support regulatory filings in the USA and Europe.

The trial is being conducted by Clovis Oncology as part of the USD380m (EUR288.1m) partnership agreement signed with Clavis Pharma in November 2009.

17 June 2010 - Investtech gave today a mid-term "buy" recommendation on Norwegian cancer drug developer Clavis Pharma ASA (OSL: CLAVIS), based on a technical analysis.

The hENT1 antibody will be used in the development of a companion diagnostic for Clavis Pharma's drug candidate CP-4126, which is in Phase II clinical trials for the treatment of pancreatic cancer.

Ultimately, its use will enable oncologists to identify patients who may show a significant benefit from treatment with Clavis Pharma's novel drug candidates.

17 February 2010 - Norwegian drug developer Clavis Pharma ASA (OSL: CLAVIS) said today its net loss narrowed to NOK24.3m in the fourth quarter of 2009 from NOK25.2m a year earlier.

8 January 2010 - Norwegian pharmaceutical company Clavis Pharma ASA (OSL: CLAVIS) said today it has named Olav Hellebo chief executive officer (CEO).

Liverpool Penguins had several younger entries who were well led by Andrew Clavis and Jamie Leigh Dunne with Elliot Warwick, Anna O Brien, Freya Kelly and Lottie Badger being their major medal winners.

Liverpool Penguins had Andrew Clavis and Freya Kelly leading their campaign along with Anna O'Brien.

Brand View broadens Ascential's eCommerce analytics offering, adding a highly complementary service (price and promotion) to the existing specialisms of sales and share and digital shelf currently provided by OCR and Clavis. Brand View introduces a new customer segment, retailers, together with coverage of off-line retail and a comprehensive and highly scalable data platform.